Opmærksomhed og øjenbevægelse i Parkinsons sygdom
30. april 2026 opdateret af: University of Nebraska
Undersøgelse af opmærksomhedens rolle i perceptuelle og kognitive konsekvenser af Parkinsons sygdom
Målet med denne observations- og interventionsundersøgelse er at forstå, hvordan terapeutisk dyb hjernestimulering (DBS) påvirker opmærksomhed, opfattelse og kognition hos deltagere med Parkinsons sygdom (PD) og essentiel rysten (ET). De vigtigste spørgsmål, det sigter mod at besvare, er:
- Ændrer nedsat kontrol af opmærksomhed og øjenbevægelse i PD, hvordan sociale signaler opfattes og fortolkes?
- Forbedrer eller forværrer terapeutiske DB'er opmærksomme og perceptuelle underskud for sociale signaler i PD og ET?
- Kan DBS optimeres til at gendanne normal opmærksomhedskontrol i PD, mens den forbliver en effektiv terapi til andre aspekter af lidelsen.
- Hvad bidrager dele af hjernen målrettet af DBS til kontrol af opmærksomheden?
Ved hjælp af et øjesporingskamera vil efterforskere studere, hvordan deltagere med PD og ET ser på og opfatter ansigtsudtryk for følelser før og efter start af DBS -terapi i sammenligning med en gruppe sunde deltagere uden ET, PD eller DBS. Deltagere med PD og ET vil se og bedømme morfede ansigtsudtryk på en computerskærm under tre forhold:
- Før du startede DBS -terapi (over ca. 1 time).
- I operationsstuen, under standardproceduren til implantat DBS -elektroder, mens deltageren er vågen (i højst 15 minutter).
- Efter start af DBS -terapi med korte eksperimentelle ændringer af DBS -stimuleringsniveau og frekvens (over ca. 1 time).
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Parkinsons sygdom (PD) er den næst mest almindelige aldersrelaterede neurodegenerative lidelse med ca. 90.000 nye tilfælde, der er diagnosticeret årligt i Nordamerika. Selvom motoriske symptomer definerer forstyrrelsen, fører PD også til kognitive og følelsesmæssige ændringer, såsom vanskeligheder med at genkende ansigtsudtryk og regulere opmærksomhed, som ofte overskygger motoriske problemer, når sygdommen skrider frem. Målet med denne undersøgelse er at bedre forstå forbindelsen mellem opmærksomhed, øjenbevægelse og følelsesmæssig opfattelse af PD, test af hypotesen, der forstyrrer opmærksomheden, fører til ændret opfattelse af ansigtsfølelser. Undersøgelsen vil også undersøge, hvordan dyb hjernestimulering (DBS) af den subthalamiske kerne (STN) påvirker disse processer, hvilket giver kritisk indsigt i de kognitive og perceptuelle konsekvenser af behandlingen.
Denne forskning adresserer et kritisk hul i forståelsen af ikke-motoriske symptomer på Parkinsons sygdom ved at undersøge, hvordan opmærksomhed, øjenbevægelse og opfattelse interagerer. Resultater vil give bevis for, hvorvidt kognitive og følelsesmæssige symptomer i PD -stammen fra nedsat opmærksomhedsstyring, der tilbyder en ny ramme til behandling af disse underskud. Derudover vil undersøgelsen kaste lys over, hvordan forskellige DBS-frekvenser påvirker opfattelsen og kognitionen, hvilket potentielt styrer personaliserede stimuleringsstrategier for at lindre både motoriske og ikke-motoriske symptomer. Den opnåede indsigt kan påvirke fremtidige terapier for PD, der fremmer både videnskabelig viden og patientpleje.
Deltagerne vil blive opdelt i tre grupper: PD, der gennemgår DBS, essentiel rysten (ET), der gennemgår DBS (som en sammenligningsgruppe for ikke-PD DBS-effekter) og sund alders- og sex-matchede kontroller. Deltagerne vil gennemføre ansigtsmorfeklassificeringsopgaver (rating ansigter som glade, neutrale eller triste) og visuelle søgeopgaver (finde ansigter blandt distraherende), mens deres øjenbevægelser spores.
Det første undersøgelsesmål er at måle, hvor ændret opmærksomhed påvirker ansigtsfølelsesopfattelse i PD ved at spore øjenbevægelser, mens deltagerne ser og kategoriserer følelsesmæssige ansigtsstimuli. Det andet mål er at karakterisere hjerneaktivitet i STN relateret til opmærksomme og perceptuelle processer under vågen DBS -kirurgi ved at fange mikroelektrodeoptagelser (MER) af neurale aktiviteter, mens deltagerne ser følelsesmæssige ansigter, hvilket giver forskere mulighed for at kortlægge STNs rolle i vejledning i opmærksomhed og øjenbevægelser. Det tredje mål er at teste, hvordan DBS -stimulering ved forskellige frekvenser (høj, lav eller slukket) påvirker opmærksomhed, øjenbevægelse og følelsesmæssig opfattelse ved at få deltagerne til at udføre visuelle og perceptuelle opgaver under forskellige DBS -indstillinger for at evaluere, hvordan hjernestimulering påvirker kognitive og perceptuelle funktioner.
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
138
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Dulce Maroni, PhD
- Telefonnummer: 402-836-9751
- E-mail: dmaroni@unmc.edu
Undersøgelse Kontakt Backup
- Navn: Christopher K Kovach, PhD
- Telefonnummer: 319-471-3372
- E-mail: ckovach@unmc.edu
Studiesteder
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68198
- Rekruttering
- University of Nebraska Medical Center
-
Kontakt:
- Dulce V Maroni, PhD
- Telefonnummer: 402-836-9751
- E-mail: dmaroni@unmc.edu
-
Ledende efterforsker:
- Christopher K Kovach, PhD
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ja
Beskrivelse
Inkluderingskriterier
Alle deltagere (mål 1):
- Evne og vilje til at give underskrevet informeret samtykke til denne undersøgelse
- Evne til at udtrykke perceptuelle vurderinger gennem en knap Tryk eller musekontrolleret edb-skyder
- Alder 19 - 90 år
DBS -deltagere (mål 1):
- Diagnose af idiopatisk Parkinsons sygdom (PD) eller essentiel rysten (ET)
- Planlagt til ny implantation af en terapeutisk DBS -enhed, der er målrettet mod subthalamisk kerne (STN), ventral mellemliggende kerne af thalamus (VIM) eller intern globus pallidus (GPI)
Sammenligningsdeltagere (AIM 1):
o Valg efter alder, der matcher til deltagere i PD -gruppen
Parkinsons sygdom (PD) og essentielle rysten (ET) deltagere (AIM 2):
- Evne og vilje til at give underskrevet informeret samtykke til denne undersøgelse
- Evne til at udtrykke perceptuelle vurderinger gennem en knap Tryk eller musekontrolleret edb-skyder
- Alder 19 - 90 år
- Planlagt til vågen DBS-implantation med kliniske mikroelektrodeoptagelser (MER)
- Villig og i stand til at deltage i opgaver under en vågen kirurgisk procedure
Parkinsons sygdom (PD) og essentielle rysten (ET) deltagere (AIM 3):
- Evne og vilje til at give underskrevet informeret samtykke til denne undersøgelse
- Evne til at udtrykke perceptuelle vurderinger gennem en knap Tryk eller musekontrolleret edb-skyder
- Alder 19 - 90 år
- Villig til at gennemgå akutte manipulationer af DBS
- I stand til at tolerere akutte ændringer af DBS
Ekskluderingskriterier
Alle deltagere (mål 1):
- Korrigeret synsskarphed utilstrækkelig til perceptuelt at bedømme ansigtsstimuli
- Manglende evne til at forstå opgaveinstruktioner eller komplette opgavekrav
DBS -deltagere (mål 1):
o Utilstrækkelig terapeutisk kontrol af motoriske symptomer til at engagere sig i opgaver, der kræver knaptryk eller brug af en mus til at kontrollere en skyder
Sunde sammenligningsdeltagere (mål 1):
o Historie om neurodegenerativ lidelse
Parkinsons sygdom (PD) og essentielle rysten (ET) deltagere (AIM 2):
- Korrigeret synsskarphed utilstrækkelig til perceptuelt at bedømme ansigtsstimuli
- Manglende evne til at forstå opgaveinstruktioner eller komplette opgavekrav
- Ikke gennemgår vågen DBS -implantation
- Ukorrigeret synsskarphed utilstrækkelig til perceptuelt at bedømme ansigtsstimuli
Parkinsons sygdom (PD) og essentielle rysten (ET) deltagere (AIM 3):
- Korrigeret synsskarphed utilstrækkelig til perceptuelt at bedømme ansigtsstimuli
- Manglende evne til at forstå opgaveinstruktioner eller komplette opgavekrav
- Fejl i DBS for at opnå en terapeutisk effekt på motoriske symptomer
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Akut ændring af DBS
Alle deltagere i den enkelte arm af denne undersøgelse vil gennemgå akut ændring af DBS -stimulering under tre betingelser i randomiseret rækkefølge i løbet af 1 time.
|
Deltagerne vil modtage dyb hjernestimulering leveret ved den klinisk bestemte terapeutiske frekvens og strøm over ca. 20 minutter.
Deltagerne vil modtage dyb hjernestimulering leveret ved den klinisk bestemte terapeutiske frekvens og reduceret (50%) strøm over cirka 20 minutter.
Deltagerne vil modtage dyb hjernestimulering leveret ved den klinisk bestemte terapeutiske strøm og reduceret (4 Hz) frekvens over ca. 20 minutter.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Facial Expression Rating
Tidsramme: Baseline (within 2 weeks pre-DBS implantation), intraoperative (Day 0; day of DBS implantation surgery, and post-operative follow-up (2-3 weeks after DBS implantation, following clinical optimization of stimulation parameters).
|
Participants will rate facial expression along a continuous scale using a computerized slider, following the affective bias task (ABT) of Bijanki et al. (2014).
The scale is anchored with three descriptors, "Very Sad" at slider value 0 (left), "Neutral", at position 0.5 (middle), and "Very Happy" at 1.0 (right).
Responses are compared between two time points: (1) at the initial pre-surgical testing session and post DBS implantation and (2) at the post-implantation session following clinical optimization of therapeutic parameters, 2-3 weeks after surgery.
The comparison will examine both the direction of any bias of the rating, against normative ratings, and the magnitude of average deviation from normative ratings.
Finally, the ratings will be incorporated into a generalized linear model of gaze position (Kovach 2014) to identify the association between perceived facial expression and characteristic fixation patterns.
|
Baseline (within 2 weeks pre-DBS implantation), intraoperative (Day 0; day of DBS implantation surgery, and post-operative follow-up (2-3 weeks after DBS implantation, following clinical optimization of stimulation parameters).
|
|
Eye Tracking
Tidsramme: Baseline (within 2 weeks pre-DBS implantation), intraoperative (Day 0; day of DBS implantation surgery, and post-operative follow-up (2-3 weeks after DBS implantation, following clinical optimization of stimulation parameters).
|
The location and duration of gaze fixations will be recorded with a remote eye tracking camera.
The location of gaze fixations will be treated as the dependent measure within a generalized linear modeling (GLM) framework for spatial point processes, described in Kovach and Adolphs (2014).
Parameter estimates of the model give the log relative risk of fixation at different locations in the visual scene as a function of the independent measures of the model.
Independent measures include the main effect of (1) Fourier basis functions encoding scene location and its interactions with (2) image rating in the affective bias task of Bijanki et.
al (2014), (3) session and (4) DBS stimulation state.
Measures derived from the GLM model will also include the statistical deviation (e.g.
Kullback-Leibler divergence) from the average distribution of fixations observed in healthy comparison subjects for each image.
|
Baseline (within 2 weeks pre-DBS implantation), intraoperative (Day 0; day of DBS implantation surgery, and post-operative follow-up (2-3 weeks after DBS implantation, following clinical optimization of stimulation parameters).
|
|
Intraoperative Microrecordings
Tidsramme: Intraoperative (Day 0; day of DBS implantation surgery).
|
During the Aim 2 portion of the study, patients undergoing awake DBS surgery as part of standard clinical care will engage in a subset of the face rating tasks during the surgery.
Invasive recordings will be obtained from DBS target structures, including STN, VIM, and GPi using microelectrodes that are placed as part of standard clinical practice.
Spike sorting will be used to identify firing of individual cells and firing rate will compared to eye movements to identify responses associated with shifts of attention in the targeted deep brain structures .
These measures will be compared across movement-disorders populations using mixed-effects linear modeling and other standard statistical procedures.
|
Intraoperative (Day 0; day of DBS implantation surgery).
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
EEG beta-band power during emotional face rating
Tidsramme: Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
Spectral power in the beta frequency band (12-30 Hz), expressed in microvolts squared (µV²) and normalized to a pre-stimulus baseline, computed from non-invasive scalp EEG over posterior electrodes during the emotional face rating component of the task.
Measurement tool: 64-channel research-grade scalp EEG with time-frequency decomposition (demodulated band transform).
Group comparisons across PD, ET, DT, and healthy controls and within-participant comparisons across DBS conditions will be made using mixed-effects linear models, comparing power at baseline and modulation of power within a -0.5 to 0.5 s peri-saccade window.
|
Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
|
EEG event-related potential (ERP) amplitude at saccade onset
Tidsramme: Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
Mean amplitude (µV) of the stimulus-locked event-related potential at saccade onset, measured over occipito-temporal electrodes during the 100-300 ms post-stimulus interval (encompassing the N170 component).
Measurement tool: 64-channel research-grade scalp EEG with stimulus-locked averaging.
|
Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
|
EEG beta burst rate, frequency and amplitude during emotional face viewing
Tidsramme: Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
Modulation of beta band activity (12-30 Hz), will be studied in scalp EEG recordings using a published method (Kovach 2026) for identifying oscillatory bursts based on estimation and decomposition of the fourth order spectrum (trispectrum).
Group comparisons across PD, ET, DT, and healthy controls and within-participant comparisons across DBS conditions will be made using mixed-effects linear models, comparing burst rate, amplitude and frequency comparing power at baseline and modulation of power within a -0.5 to 0.5 s peri-saccade window.
|
Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
|
LFP beta-band (12-30 Hz) power during emotional face viewing
Tidsramme: Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
Spectral power in the beta band (12-30 Hz), expressed in microvolts squared (µV²), recorded from chronically implanted DBS electrodes targeting the subthalamic nucleus during eye-tracked task performance.
Measurement tool: voltage telemetry through clinical leads using the BrainSense capability of the Medtronic Percept implantable pulse generator.
Power will be computed via time-frequency decomposition (demodulated band transform) and compared across DBS conditions (normal therapeutic, reduced current, reduced frequency) and across movement-disorder populations using mixed-effects linear models.
|
Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
|
LFP beta burst rate, frequency and amplitude during emotional face viewing
Tidsramme: Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
Modulation of beta band activity (12-30 Hz), will be studied in intracranial LFP recordings using a published method (Kovach et al. 2026) for identifying oscillatory bursts based on estimation and decomposition of the fourth order spectrum (trispectrum).
Group comparisons across PD, ET, DT, and healthy controls and within-participant comparisons across DBS conditions will be made using mixed-effects linear models, comparing burst rate, amplitude and frequency comparing power at baseline and modulation of power within a -0.5 to 0.5 s peri-saccade window.
|
Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
|
LFP theta-band (4-8 Hz) power during emotional face viewing
Tidsramme: Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
Spectral power in the theta frequency band (4-8 Hz), expressed in microvolts squared (µV²) and normalized to a pre-stimulus baseline, computed from non-invasive scalp EEG over fronto-central electrodes during presentation of morphed emotional face stimuli in the affective bias task (Bijanki et al., 2014).
Measurement tool: voltage telemetry through clinical leads using the BrainSense capability of the Medtronic Percept implantable pulse generator.Group comparisons across PD, ET, DT, and healthy controls and within-participant comparisons across DBS conditions will be made using mixed-effects linear models, comparing power at baseline and modulation of power within a -0.5 to 0.5 s peri-saccade window.
|
Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
|
EEG-LFP coherence during emotional face viewing
Tidsramme: Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
Coherence between scalp EEG recordings and intracranial LFP recordings will be examined across multiple frequencies from 1 Hz to 30 Hz using a time-frequency decomposition (demodulated band transform, Kovach 2016) with 1 Hz frequency bins.
Measurement tool: 64 channel scalp EEG and concurrent voltage telemetry through clinical leads using the BrainSense capability of the Medtronic Percept implantable pulse generator.
Group comparisons of subject-level coherence values across PD, ET, DT, and healthy controls and within-participant comparisons across DBS conditions will be made using mixed-effects linear models, comparing power at baseline and modulation of power within a -0.5 to 0.5 s peri-saccade window.
|
Single experimental visit during the Aim 3 study session (third study visit; through study completion, an average of 6 months).
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Christopher K Kovach, PhD, University of Nebraska
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Tottenham N, Tanaka JW, Leon AC, McCarry T, Nurse M, Hare TA, Marcus DJ, Westerlund A, Casey BJ, Nelson C. The NimStim set of facial expressions: judgments from untrained research participants. Psychiatry Res. 2009 Aug 15;168(3):242-9. doi: 10.1016/j.psychres.2008.05.006. Epub 2009 Jun 28.
- Doyon J, Bellec P, Amsel R, Penhune V, Monchi O, Carrier J, Lehericy S, Benali H. Contributions of the basal ganglia and functionally related brain structures to motor learning. Behav Brain Res. 2009 Apr 12;199(1):61-75. doi: 10.1016/j.bbr.2008.11.012. Epub 2008 Nov 17.
- Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3-S8. doi: 10.3233/JPD-181474.
- Shibasaki H, Tsuji S, Kuroiwa Y. Oculomotor abnormalities in Parkinson's disease. Arch Neurol. 1979 Jun;36(6):360-4. doi: 10.1001/archneur.1979.00500420070009.
- McIntyre CC, Hahn PJ. Network perspectives on the mechanisms of deep brain stimulation. Neurobiol Dis. 2010 Jun;38(3):329-37. doi: 10.1016/j.nbd.2009.09.022. Epub 2009 Oct 3.
- Sugita Y. Face perception in monkeys reared with no exposure to faces. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):394-8. doi: 10.1073/pnas.0706079105. Epub 2008 Jan 2.
- W. Penny and A. Holmes. Random effects analysis. Statistical parametric mapping: The analysis of functional brain images, 156:165, 2007.
- C. K. Kovach and M. A. Howard III. Decomposition of higher-order spectra for blind multiple-input deconvolution, pattern identification and separation. Signal Processing, 165:357-379, 2019.
- C. Kovach, J. Moreira, J. Berger, M. Howard III, L. Gwilliams, A. Fallah, L. Comstock, and E. Mendes. Higher-order spectral decomposition applied to spike sorting. Feb. 2023.
- X. Fan, M. Mocchi, B. Pascuzzi, J. Xiao, B. A. Metzger, R. K. Mathura, C. Hacker, J. A. Adkinson, E. Bartoli, S. Elhassa, et al. Brain mechanisms underlying the emotion processing bias in treatment- resistant depression. Nature Mental Health, pages 1-10, 2024.
- Metzger BA, Kalva P, Mocchi MM, Cui B, Adkinson JA, Wang Z, Mathura R, Kanja K, Gavvala J, Krishnan V, Lin L, Maheshwari A, Shofty B, Magnotti JF, Willie JT, Sheth SA, Bijanki KR. Intracranial stimulation and EEG feature analysis reveal affective salience network specialization. Brain. 2023 Oct 3;146(10):4366-4377. doi: 10.1093/brain/awad200.
- Bijanki KR, Kovach CK, McCormick LM, Kawasaki H, Dlouhy BJ, Feinstein J, Jones RD, Howard MA 3rd. Case report: stimulation of the right amygdala induces transient changes in affective bias. Brain Stimul. 2014 Sep-Oct;7(5):690-3. doi: 10.1016/j.brs.2014.05.005. Epub 2014 May 24.
- Marneweck M, Loftus A, Hammond G. Psychophysical measures of sensitivity to facial expression of emotion. Front Psychol. 2013 Feb 20;4:63. doi: 10.3389/fpsyg.2013.00063. eCollection 2013.
- Hershey T, Campbell MC, Videen TO, Lugar HM, Weaver PM, Hartlein J, Karimi M, Tabbal SD, Perlmutter JS. Mapping Go-No-Go performance within the subthalamic nucleus region. Brain. 2010 Dec;133(Pt 12):3625-34. doi: 10.1093/brain/awq256. Epub 2010 Sep 20.
- McIntosh LG, Mannava S, Camalier CR, Folley BS, Albritton A, Konrad PE, Charles D, Park S, Neimat JS. Emotion recognition in early Parkinson's disease patients undergoing deep brain stimulation or dopaminergic therapy: a comparison to healthy participants. Front Aging Neurosci. 2015 Jan 21;6:349. doi: 10.3389/fnagi.2014.00349. eCollection 2014.
- Albuquerque L, Coelho M, Martins M, Guedes LC, Rosa MM, Ferreira JJ, Cattoni MB, Carvalho H, Ferreira AG, Martins IP. STN-DBS does not change emotion recognition in advanced Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb;20(2):166-9. doi: 10.1016/j.parkreldis.2013.10.010. Epub 2013 Oct 18.
- Berney A, Panisset M, Sadikot AF, Ptito A, Dagher A, Fraraccio M, Savard G, Pell M, Benkelfat C. Mood stability during acute stimulator challenge in Parkinson's disease patients under long-term treatment with subthalamic deep brain stimulation. Mov Disord. 2007 Jun 15;22(8):1093-6. doi: 10.1002/mds.21245.
- Schneider F, Habel U, Volkmann J, Regel S, Kornischka J, Sturm V, Freund HJ. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. Arch Gen Psychiatry. 2003 Mar;60(3):296-302. doi: 10.1001/archpsyc.60.3.296.
- Wagenbreth C, Wattenberg L, Heinze HJ, Zaehle T. Implicit and explicit processing of emotional facial expressions in Parkinson's disease. Behav Brain Res. 2016 Apr 15;303:182-90. doi: 10.1016/j.bbr.2016.01.059. Epub 2016 Feb 2.
- Mermillod M, Mondillon L, Rieu I, Devaux D, Chambres P, Auxiette C, Dalens H, Coulangeon LM, Jalenques I, Durif F. Dopamine replacement therapy and deep brain stimulation of the subthalamic nuclei induce modulation of emotional processes at different spatial frequencies in Parkinson's disease. J Parkinsons Dis. 2014;4(1):97-110. doi: 10.3233/JPD-130256.
- Mondillon L, Mermillod M, Musca SC, Rieu I, Vidal T, Chambres P, Auxiette C, Dalens H, Marie Coulangeon L, Jalenques I, Lemaire JJ, Ulla M, Derost P, Marques A, Durif F. The combined effect of subthalamic nuclei deep brain stimulation and L-dopa increases emotion recognition in Parkinson's disease. Neuropsychologia. 2012 Oct;50(12):2869-2879. doi: 10.1016/j.neuropsychologia.2012.08.016. Epub 2012 Aug 28.
- Peron J, Biseul I, Leray E, Vicente S, Le Jeune F, Drapier S, Drapier D, Sauleau P, Haegelen C, Verin M. Subthalamic nucleus stimulation affects fear and sadness recognition in Parkinson's disease. Neuropsychology. 2010 Jan;24(1):1-8. doi: 10.1037/a0017433.
- Drapier D, Peron J, Leray E, Sauleau P, Biseul I, Drapier S, Le Jeune F, Travers D, Bourguignon A, Haegelen C, Millet B, Verin M. Emotion recognition impairment and apathy after subthalamic nucleus stimulation in Parkinson's disease have separate neural substrates. Neuropsychologia. 2008 Sep;46(11):2796-801. doi: 10.1016/j.neuropsychologia.2008.05.006. Epub 2008 May 20.
- Biseul I, Sauleau P, Haegelen C, Trebon P, Drapier D, Raoul S, Drapier S, Lallement F, Rivier I, Lajat Y, Verin M. Fear recognition is impaired by subthalamic nucleus stimulation in Parkinson's disease. Neuropsychologia. 2005;43(7):1054-9. doi: 10.1016/j.neuropsychologia.2004.10.006. Epub 2004 Dec 30.
- Dujardin K, Blairy S, Defebvre L, Krystkowiak P, Hess U, Blond S, Destee A. Subthalamic nucleus stimulation induces deficits in decoding emotional facial expressions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):202-8.
- Schroeder U, Kuehler A, Hennenlotter A, Haslinger B, Tronnier VM, Krause M, Pfister R, Sprengelmeyer R, Lange KW, Ceballos-Baumann AO. Facial expression recognition and subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):648-50. doi: 10.1136/jnnp.2003.019794.
- Pinkhardt EH, Jurgens R, Lule D, Heimrath J, Ludolph AC, Becker W, Kassubek J. Eye movement impairments in Parkinson's disease: possible role of extradopaminergic mechanisms. BMC Neurol. 2012 Feb 29;12:5. doi: 10.1186/1471-2377-12-5.
- Dec-Cwiek M, Tutaj M, Gracies JM, Volkmann J, Rudzinska M, Slowik A, Szczudlik A. Opposite effects of l-dopa and DBS-STN on saccadic eye movements in advanced Parkinson's disease. Neurol Neurochir Pol. 2017 Sep-Oct;51(5):354-360. doi: 10.1016/j.pjnns.2017.06.002. Epub 2017 Jun 24.
- Temel Y, Visser-Vandewalle V, Carpenter RHS. Saccadic latency during electrical stimulation of the human subthalamic nucleus. Curr Biol. 2008 May 20;18(10):R412-R414. doi: 10.1016/j.cub.2008.03.008. No abstract available.
- Fischer P, Ossandon JP, Keyser J, Gulberti A, Wilming N, Hamel W, Koppen J, Buhmann C, Westphal M, Gerloff C, Moll CK, Engel AK, Konig P. STN-DBS Reduces Saccadic Hypometria but Not Visuospatial Bias in Parkinson's Disease Patients. Front Behav Neurosci. 2016 May 3;10:85. doi: 10.3389/fnbeh.2016.00085. eCollection 2016.
- Nilsson MH, Patel M, Rehncrona S, Magnusson M, Fransson PA. Subthalamic deep brain stimulation improves smooth pursuit and saccade performance in patients with Parkinson's disease. J Neuroeng Rehabil. 2013 Apr 3;10:33. doi: 10.1186/1743-0003-10-33.
- Klarendic M, Kaski D. Deep brain stimulation and eye movements. Eur J Neurosci. 2021 Apr;53(7):2344-2361. doi: 10.1111/ejn.14898. Epub 2020 Jul 27.
- Fawcett AP, Cunic D, Hamani C, Hodaie M, Lozano AM, Chen R, Hutchison WD. Saccade-related potentials recorded from human subthalamic nucleus. Clin Neurophysiol. 2007 Jan;118(1):155-63. doi: 10.1016/j.clinph.2006.09.016. Epub 2006 Nov 9.
- Kovach CK, Adolphs R. Investigating attention in complex visual search. Vision Res. 2015 Nov;116(Pt B):127-41. doi: 10.1016/j.visres.2014.11.011. Epub 2014 Dec 8.
- Kovach CK, Sutterer MJ, Rushia SN, Teriakidis A, Jenison RL. Two systems drive attention to rewards. Front Psychol. 2014 Feb 5;5:46. doi: 10.3389/fpsyg.2014.00046. eCollection 2014.
- Beylergil SB, Kilbane C, Shaikh AG, Ghasia FF. Eye movements in Parkinson's disease during visual search. J Neurol Sci. 2022 Sep 15;440:120299. doi: 10.1016/j.jns.2022.120299. Epub 2022 May 28.
- Waldthaler J, Stock L, Student J, Sommerkorn J, Dowiasch S, Timmermann L. Antisaccades in Parkinson's Disease: A Meta-Analysis. Neuropsychol Rev. 2021 Dec;31(4):628-642. doi: 10.1007/s11065-021-09489-1. Epub 2021 Mar 19.
- Clark US, Neargarder S, Cronin-Golomb A. Visual exploration of emotional facial expressions in Parkinson's disease. Neuropsychologia. 2010 Jun;48(7):1901-13. doi: 10.1016/j.neuropsychologia.2010.03.006. Epub 2010 Mar 15.
- Hodgson TL, Tiesman B, Owen AM, Kennard C. Abnormal gaze strategies during problem solving in Parkinson's disease. Neuropsychologia. 2002;40(4):411-22. doi: 10.1016/s0028-3932(01)00099-9.
- Antoniades CA, Spering M. Eye movements in Parkinson's disease: from neurophysiological mechanisms to diagnostic tools. Trends Neurosci. 2024 Jan;47(1):71-83. doi: 10.1016/j.tins.2023.11.001. Epub 2023 Dec 2.
- Zhang Y, Yan A, Liu B, Wan Y, Zhao Y, Liu Y, Tan J, Song L, Gu Y, Liu Z. Oculomotor Performances Are Associated With Motor and Non-motor Symptoms in Parkinson's Disease. Front Neurol. 2018 Nov 28;9:960. doi: 10.3389/fneur.2018.00960. eCollection 2018.
- Pretegiani E, Optican LM. Eye Movements in Parkinson's Disease and Inherited Parkinsonian Syndromes. Front Neurol. 2017 Nov 9;8:592. doi: 10.3389/fneur.2017.00592. eCollection 2017.
- Pinkhardt EH, Kassubek J. Ocular motor abnormalities in Parkinsonian syndromes. Parkinsonism Relat Disord. 2011 May;17(4):223-30. doi: 10.1016/j.parkreldis.2010.08.004. Epub 2010 Aug 30.
- Assogna F, Pontieri FE, Caltagirone C, Spalletta G. The recognition of facial emotion expressions in Parkinson's disease. Eur Neuropsychopharmacol. 2008 Nov;18(11):835-48. doi: 10.1016/j.euroneuro.2008.07.004. Epub 2008 Aug 15.
- Pell MD, Leonard CL. Facial expression decoding in early Parkinson's disease. Brain Res Cogn Brain Res. 2005 May;23(2-3):327-40. doi: 10.1016/j.cogbrainres.2004.11.004. Epub 2005 Jan 7.
- Adolphs R, Schul R, Tranel D. Intact recognition of facial emotion in Parkinson's disease. Neuropsychology. 1998 Apr;12(2):253-8. doi: 10.1037//0894-4105.12.2.253.
- Dodich A, Funghi G, Meli C, Pennacchio M, Longo C, Malaguti MC, Di Giacopo R, Zappini F, Turella L, Papagno C. Deficits in Emotion Recognition and Theory of Mind in Parkinson's Disease Patients With and Without Cognitive Impairments. Front Psychol. 2022 May 13;13:866809. doi: 10.3389/fpsyg.2022.866809. eCollection 2022.
- Mattavelli G, Barvas E, Longo C, Zappini F, Ottaviani D, Malaguti MC, Pellegrini M, Papagno C. Facial expressions recognition and discrimination in Parkinson's disease. J Neuropsychol. 2021 Mar;15(1):46-68. doi: 10.1111/jnp.12209. Epub 2020 Apr 22.
- Coundouris SP, Adams AG, Grainger SA, Henry JD. Social perceptual function in parkinson's disease: A meta-analysis. Neurosci Biobehav Rev. 2019 Sep;104:255-267. doi: 10.1016/j.neubiorev.2019.07.011. Epub 2019 Jul 20.
- Marneweck M, Hammond G. Discriminating facial expressions of emotion and its link with perceiving visual form in Parkinson's disease. J Neurol Sci. 2014 Nov 15;346(1-2):149-55. doi: 10.1016/j.jns.2014.08.014. Epub 2014 Aug 20.
- Ariatti A, Benuzzi F, Nichelli P. Recognition of emotions from visual and prosodic cues in Parkinson's disease. Neurol Sci. 2008 Sep;29(4):219-27. doi: 10.1007/s10072-008-0971-9. Epub 2008 Sep 20.
- Suzuki A, Hoshino T, Shigemasu K, Kawamura M. Disgust-specific impairment of facial expression recognition in Parkinson's disease. Brain. 2006 Mar;129(Pt 3):707-17. doi: 10.1093/brain/awl011. Epub 2006 Jan 16.
- Dujardin K, Blairy S, Defebvre L, Duhem S, Noel Y, Hess U, Destee A. Deficits in decoding emotional facial expressions in Parkinson's disease. Neuropsychologia. 2004;42(2):239-50. doi: 10.1016/s0028-3932(03)00154-4.
- Simons G, Pasqualini MC, Reddy V, Wood J. Emotional and nonemotional facial expressions in people with Parkinson's disease. J Int Neuropsychol Soc. 2004 Jul;10(4):521-35. doi: 10.1017/S135561770410413X.
- Prenger MTM, Madray R, Van Hedger K, Anello M, MacDonald PA. Social Symptoms of Parkinson's Disease. Parkinsons Dis. 2020 Dec 31;2020:8846544. doi: 10.1155/2020/8846544. eCollection 2020.
- Pell MD, Monetta L, Rothermich K, Kotz SA, Cheang HS, McDonald S. Social perception in adults with Parkinson's disease. Neuropsychology. 2014 Nov;28(6):905-16. doi: 10.1037/neu0000090. Epub 2014 Jun 2.
- Peron J, Dondaine T, Le Jeune F, Grandjean D, Verin M. Emotional processing in Parkinson's disease: a systematic review. Mov Disord. 2012 Feb;27(2):186-99. doi: 10.1002/mds.24025. Epub 2011 Dec 9.
- Caap-Ahlgren M, Dehlin O. Factors of importance to the caregiver burden experienced by family caregivers of Parkinson's disease patients. Aging Clin Exp Res. 2002 Oct;14(5):371-7. doi: 10.1007/BF03324464.
- Jacobs DH, Shuren J, Bowers D, Heilman KM. Emotional facial imagery, perception, and expression in Parkinson's disease. Neurology. 1995 Sep;45(9):1696-702. doi: 10.1212/wnl.45.9.1696.
- Isoda M, Hikosaka O. Switching from automatic to controlled action by monkey medial frontal cortex. Nat Neurosci. 2007 Feb;10(2):240-8. doi: 10.1038/nn1830. Epub 2007 Jan 21.
- Siegert RJ, Taylor KD, Weatherall M, Abernethy DA. Is implicit sequence learning impaired in Parkinson's disease? A meta-analysis. Neuropsychology. 2006 Jul;20(4):490-5. doi: 10.1037/0894-4105.20.4.490.
- Jahanshahi M, Obeso I, Rothwell JC, Obeso JA. A fronto-striato-subthalamic-pallidal network for goal-directed and habitual inhibition. Nat Rev Neurosci. 2015 Dec;16(12):719-32. doi: 10.1038/nrn4038. Epub 2015 Nov 4.
- Arcaro MJ, Schade PF, Vincent JL, Ponce CR, Livingstone MS. Seeing faces is necessary for face-domain formation. Nat Neurosci. 2017 Oct;20(10):1404-1412. doi: 10.1038/nn.4635. Epub 2017 Sep 4.
- Kundel HL, Nodine CF, Krupinski EA, Mello-Thoms C. Using gaze-tracking data and mixture distribution analysis to support a holistic model for the detection of cancers on mammograms. Acad Radiol. 2008 Jul;15(7):881-6. doi: 10.1016/j.acra.2008.01.023.
- Charness N, Reingold EM, Pomplun M, Stampe DM. The perceptual aspect of skilled performance in chess: evidence from eye movements. Mem Cognit. 2001 Dec;29(8):1146-52. doi: 10.3758/bf03206384.
- Wolfe JM, Butcher SJ, Lee C, Hyle M. Changing your mind: on the contributions of top-down and bottom-up guidance in visual search for feature singletons. J Exp Psychol Hum Percept Perform. 2003 Apr;29(2):483-502. doi: 10.1037/0096-1523.29.2.483.
- Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology. 2008 May 13;70(20):1916-25. doi: 10.1212/01.wnl.0000312279.49272.9f. No abstract available.
- Brown RG, Marsden CD. Internal versus external cues and the control of attention in Parkinson's disease. Brain. 1988 Apr;111 ( Pt 2):323-45. doi: 10.1093/brain/111.2.323.
- Schurgin MW, Nelson J, Iida S, Ohira H, Chiao JY, Franconeri SL. Eye movements during emotion recognition in faces. J Vis. 2014 Nov 18;14(13):14. doi: 10.1167/14.13.14.
- Oberauer K. Working Memory and Attention - A Conceptual Analysis and Review. J Cogn. 2019 Aug 8;2(1):36. doi: 10.5334/joc.58.
- D. A. Norman and T. Shallice. Attention to action: Willed and automatic control of behavior. In R. Davidson, G. Schwartz, and S. D, editors, Consciousness and self regulation: Advances in Research, Volume IV. New York: Plenum Press, 1986.
- Dirnberger G, Jahanshahi M. Executive dysfunction in Parkinson's disease: a review. J Neuropsychol. 2013 Sep;7(2):193-224. doi: 10.1111/jnp.12028.
- Ho MW, Chien SH, Lu MK, Chen JC, Aoh Y, Chen CM, Lane HY, Tsai CH. Impairments in face discrimination and emotion recognition are related to aging and cognitive dysfunctions in Parkinson's disease with dementia. Sci Rep. 2020 Mar 9;10(1):4367. doi: 10.1038/s41598-020-61310-w.
- K. E. Thorpe, A. I. Levey, and J. Thomas. Us burden of neurodegenerative disease. Partnership to Fight Chronic Disease (PFCD), pages 1-13, 2021.
- Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, Ray Dorsey E, Dahodwala N, Cintina I, Hogan P, Thompson T. Current and projected future economic burden of Parkinson's disease in the U.S. NPJ Parkinsons Dis. 2020 Jul 9;6:15. doi: 10.1038/s41531-020-0117-1. eCollection 2020.
- Willis AW, Roberts E, Beck JC, Fiske B, Ross W, Savica R, Van Den Eeden SK, Tanner CM, Marras C; Parkinson's Foundation P4 Group. Incidence of Parkinson disease in North America. NPJ Parkinsons Dis. 2022 Dec 15;8(1):170. doi: 10.1038/s41531-022-00410-y.
- Kelley R, Flouty O, Emmons EB, Kim Y, Kingyon J, Wessel JR, Oya H, Greenlee JD, Narayanan NS. A human prefrontal-subthalamic circuit for cognitive control. Brain. 2018 Jan 1;141(1):205-216. doi: 10.1093/brain/awx300.
- Yugeta A, Terao Y, Fukuda H, Hikosaka O, Yokochi F, Okiyama R, Taniguchi M, Takahashi H, Hamada I, Hanajima R, Ugawa Y. Effects of STN stimulation on the initiation and inhibition of saccade in Parkinson disease. Neurology. 2010 Mar 2;74(9):743-8. doi: 10.1212/WNL.0b013e3181d31e0b.
- Isoda M, Hikosaka O. Role for subthalamic nucleus neurons in switching from automatic to controlled eye movement. J Neurosci. 2008 Jul 9;28(28):7209-18. doi: 10.1523/JNEUROSCI.0487-08.2008.
- Waldthaler J, Kruger-Zechlin C, Stock L, Deeb Z, Timmermann L. New insights into facial emotion recognition in Parkinson's disease with and without mild cognitive impairment from visual scanning patterns. Clin Park Relat Disord. 2019 Nov 20;1:102-108. doi: 10.1016/j.prdoa.2019.11.003. eCollection 2019.
- Hannula DE, Althoff RR, Warren DE, Riggs L, Cohen NJ, Ryan JD. Worth a glance: using eye movements to investigate the cognitive neuroscience of memory. Front Hum Neurosci. 2010 Oct 8;4:166. doi: 10.3389/fnhum.2010.00166. eCollection 2010.
- Frei K. Abnormalities of smooth pursuit in Parkinson's disease: A systematic review. Clin Park Relat Disord. 2020 Dec 17;4:100085. doi: 10.1016/j.prdoa.2020.100085. eCollection 2021.
- de Haan B, Morgan PS, Rorden C. Covert orienting of attention and overt eye movements activate identical brain regions. Brain Res. 2008 Apr 14;1204:102-11. doi: 10.1016/j.brainres.2008.01.105. Epub 2008 Feb 19.
- Tokushige SI, Matsuda SI, Oyama G, Shimo Y, Umemura A, Sasaki T, Inomata-Terada S, Yugeta A, Hamada M, Ugawa Y, Tsuji S, Hattori N, Terao Y. Effect of subthalamic nucleus deep brain stimulation on visual scanning. Clin Neurophysiol. 2018 Nov;129(11):2421-2432. doi: 10.1016/j.clinph.2018.08.003. Epub 2018 Aug 30.
- Fawcett AP, Gonzalez EG, Moro E, Steinbach MJ, Lozano AM, Hutchison WD. Subthalamic nucleus deep brain stimulation improves saccades in Parkinson's disease. Neuromodulation. 2010 Jan;13(1):17-25. doi: 10.1111/j.1525-1403.2009.00246.x. Epub 2009 Nov 13.
- Blekher T, Weaver M, Rupp J, Nichols WC, Hui SL, Gray J, Yee RD, Wojcieszek J, Foroud T. Multiple step pattern as a biomarker in Parkinson disease. Parkinsonism Relat Disord. 2009 Aug;15(7):506-10. doi: 10.1016/j.parkreldis.2009.01.002. Epub 2009 Feb 10.
- Hikosaka O, Takikawa Y, Kawagoe R. Role of the basal ganglia in the control of purposive saccadic eye movements. Physiol Rev. 2000 Jul;80(3):953-78. doi: 10.1152/physrev.2000.80.3.953.
- Lieberman A. Depression in Parkinson's disease -- a review. Acta Neurol Scand. 2006 Jan;113(1):1-8. doi: 10.1111/j.1600-0404.2006.00536.x.
- Bek J, Poliakoff E, Lander K. Measuring emotion recognition by people with Parkinson's disease using eye-tracking with dynamic facial expressions. J Neurosci Methods. 2020 Feb 1;331:108524. doi: 10.1016/j.jneumeth.2019.108524. Epub 2019 Nov 17.
- Wagenbreth C, Kuehne M, Heinze HJ, Zaehle T. Deep Brain Stimulation of the Subthalamic Nucleus Influences Facial Emotion Recognition in Patients With Parkinson's Disease: A Review. Front Psychol. 2019 Dec 3;10:2638. doi: 10.3389/fpsyg.2019.02638. eCollection 2019.
- Argaud S, Verin M, Sauleau P, Grandjean D. Facial emotion recognition in Parkinson's disease: A review and new hypotheses. Mov Disord. 2018 Apr;33(4):554-567. doi: 10.1002/mds.27305. Epub 2018 Feb 23.
- Assogna F, Cravello L, Orfei MD, Cellupica N, Caltagirone C, Spalletta G. Alexithymia in Parkinson's disease: A systematic review of the literature. Parkinsonism Relat Disord. 2016 Jul;28:1-11. doi: 10.1016/j.parkreldis.2016.03.021. Epub 2016 Mar 30.
- Gray HM, Tickle-Degnen L. A meta-analysis of performance on emotion recognition tasks in Parkinson's disease. Neuropsychology. 2010 Mar;24(2):176-91. doi: 10.1037/a0018104.
- Clark US, Neargarder S, Cronin-Golomb A. Specific impairments in the recognition of emotional facial expressions in Parkinson's disease. Neuropsychologia. 2008;46(9):2300-9. doi: 10.1016/j.neuropsychologia.2008.03.014. Epub 2008 Mar 30.
- Yip JT, Lee TM, Ho SL, Tsang KL, Li LS. Emotion recognition in patients with idiopathic Parkinson's disease. Mov Disord. 2003 Oct;18(10):1115-22. doi: 10.1002/mds.10497.
- Soh C, Hervault M, Chalkley NH, Moore CM, Rohl A, Zhang Q, Uc EY, Greenlee JDW, Wessel JR. The human subthalamic nucleus transiently inhibits active attentional processes. Brain. 2024 Sep 3;147(9):3204-3215. doi: 10.1093/brain/awae068.
- Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Collerton D, Taylor JP, Burn DJ; ICICLE-PD study group. Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. Parkinsonism Relat Disord. 2016 Jun;27:47-53. doi: 10.1016/j.parkreldis.2016.04.009. Epub 2016 Apr 11.
- Botha H, Carr J. Attention and visual dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2012 Jul;18(6):742-7. doi: 10.1016/j.parkreldis.2012.03.004. Epub 2012 Apr 11.
- Stam CJ, Visser SL, Op de Coul AA, De Sonneville LM, Schellens RL, Brunia CH, de Smet JS, Gielen G. Disturbed frontal regulation of attention in Parkinson's disease. Brain. 1993 Oct;116 ( Pt 5):1139-58. doi: 10.1093/brain/116.5.1139.
- Wright MJ, Burns RJ, Geffen GM, Geffen LB. Covert orientation of visual attention in Parkinson's disease: an impairment in the maintenance of attention. Neuropsychologia. 1990;28(2):151-9. doi: 10.1016/0028-3932(90)90097-8.
- LeWitt PA, Chaudhuri KR. Unmet needs in Parkinson disease: Motor and non-motor. Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S7-S12. doi: 10.1016/j.parkreldis.2020.09.024. Epub 2020 Dec 19.
- Goldman JG, Vernaleo BA, Camicioli R, Dahodwala N, Dobkin RD, Ellis T, Galvin JE, Marras C, Edwards J, Fields J, Golden R, Karlawish J, Levin B, Shulman L, Smith G, Tangney C, Thomas CA, Troster AI, Uc EY, Coyan N, Ellman C, Ellman M, Hoffman C, Hoffman S, Simmonds D. Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. NPJ Parkinsons Dis. 2018 Jun 26;4:19. doi: 10.1038/s41531-018-0055-3. eCollection 2018.
- Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol. 1997 Jan;244(1):2-8. doi: 10.1007/pl00007725.
- Sprengelmeyer R, Young AW, Mahn K, Schroeder U, Woitalla D, Buttner T, Kuhn W, Przuntek H. Facial expression recognition in people with medicated and unmedicated Parkinson's disease. Neuropsychologia. 2003;41(8):1047-57. doi: 10.1016/s0028-3932(02)00295-6.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
22. september 2025
Primær færdiggørelse (Anslået)
1. februar 2028
Studieafslutning (Anslået)
1. august 2028
Datoer for studieregistrering
Først indsendt
14. marts 2025
Først indsendt, der opfyldte QC-kriterier
20. marts 2025
Først opslået (Faktiske)
27. marts 2025
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
5. maj 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
30. april 2026
Sidst verificeret
1. marts 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 0082-25-FB
- P20GM130447 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .